ACURATE TA™ Valve Implantation: SAVI Registry (Surveillance Plan #2011-02) (TA-SAVI)
Launched by SYMETIS SA · May 3, 2017
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
A single arm, prospective, multicenter, non-randomized and open registry up to 1 Year Follow-up with the Symetis ACURATE TA™ which is an aortic bioprosthesis for minimal invasive implantation via transapical access to treat patients with severe symptomatic aortic stenosis where surgical aortic valve replacement (SAVR) via open surgery is considered to be associated with high surgical risk for evaluating the safety and performance of the implantation and the safety at 30-Day Follow-up.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient has severe aortic stenosis
- • Native aortic annulus diameter from ≥ 21mm up to ≤ 27mm
- • Patient willing to participate in the study and provides signed EC-approved informed consent
- • The subject and treating physician agree the subject will return for all required post-procedure follow-up visits
- Exclusion Criteria:
- • Patients are excluded from the registry if they are not eligible for transcatheter treatment of severe aortic stenosis with the ACURATE TA™ and Delivery System as per the Instructions For Use.
About Symetis Sa
Symetis SA is a pioneering medical device company specializing in innovative solutions for structural heart diseases. With a strong focus on transcatheter interventions, Symetis develops advanced technologies aimed at improving patient outcomes and enhancing the quality of care in cardiovascular medicine. The company is committed to rigorous clinical research and development, collaborating with healthcare professionals and institutions to ensure the safety and efficacy of its products. Through its dedication to innovation and excellence, Symetis SA strives to lead the way in transforming the treatment landscape for patients with heart conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aachen, , Germany
Bologna, , Italy
Leipzig, , Germany
Bad Berka, , Germany
Regensburg, , Germany
Stuttgart, , Germany
Bad Nauheim, , Germany
Buenos Aires, , Argentina
Bad Neustadt, , Germany
Bad Rothenfelde, , Germany
Dresden, , Germany
Essen, , Germany
Hamburg, , Germany
Karlsruhe, , Germany
Köln, , Germany
Mainz, , Germany
Bern, , Switzerland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials